Wockhardt Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Wockhardt Ltd. from all sources in a single place.

Load latest

Wockhardt Ltd.

31 Jan 2025

1718.50

-0.53%

Company Update

WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Pursuant to Regulation 30 of SEBI Listing Regulations, please find enclosed Press Release - "Wockhardt''s Zaynich (Zidebactam/Cefepime, WCK 5222) achieves highest-ever efficacy meeting superiority in a global, pivotal, registration-enabling Phase III study in complicated urinary infection (cUTI) achieving 96.8% clinical cure rate"

pdf

Wockhardt Ltd.

14 Jan 2025

1718.50

-0.53%

Company Update

WOCKHARDT LTD. - 532300 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, please find attached the Compliance Certificate received from MUFG Intime India Pvt Ltd (Formerly known as Link Intime India Pvt Ltd), RTA of the Company for the Quarter ended 31st December, 2024.

pdf

Wockhardt Ltd.

13 Jan 2025

1718.50

-0.53%

Wockhardt Sees New Drugs To Fight Superbugs As Next Growth Driver

NDTV Profit

Wockhardt, founded in 1967, now has six novel formulations in the pipeline, with a second drug Zaynich also expected to launch later in 2025 to tackle complex hospital infections.

Wockhardt Ltd. has gained 29.17% in the last 1 Month

Wockhardt's Zaynich antibiotic achieves 97% efficacy against carbapenem-resistant bacteria

Business Line | 13 Jan 2025 2 more

Wockhardt Ltd.

13 Jan 2025

1718.50

-0.53%

Company Update

WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Pursuant to Regulation 30 of SEBI Listing Regulations, please find attached Press Release titled "Zaynich(Zidebactum/Cefepime. WCK 5222)achieves over 97% Efficacy in Clinical Study for serious infections caused by by Meropenem-Resistant Gram-Negative Pathogens."

pdf

Wockhardt Ltd.

07 Jan 2025

1718.50

-0.53%

Wockhardt Eyes Rs 400-Crore Revenue From Pneumonia Antibiotic Miqnaf

NDTV Profit

Miqnaf is an antibiotic for treatment of community-acquired bacterial pneumonia, including those caused by multi-drug resistant pathogens.

Promoters pledged 1.26% of shares in last quarter. Total pledge stands at 18.24% of promoter holdings

Wockhardt Ltd.

03 Jan 2025

1718.50

-0.53%

Wockhardt's novel antibiotic gets CDSCO approval

Business Line

The antibiotic is an ultra-short course - once-a-day, 3-day treatment for Community-Acquired Bacterial Pneumonia (CABP) in adults, including those caused by multi-drug resistant (MDR) pathogens, the company said

Wockhardt Ltd. high volume past week with price gain of 11.11.

Wockhardt shares surge 9.5%, touch 9-year high on regulatory nod for antibiotic drug

livemint | 03 Jan 2025 1 more

Wockhardt Ltd.

02 Jan 2025

1718.50

-0.53%

Company Update

WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Pursuant to Regulation 30 of the Listing Regulations, please find attached Press Release titled- Indian Drug Regulator Approves Wockhardt''s New Generation Oral Antibiotic MiqnafR (Nafithromycin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP).

pdf

Wockhardt Ltd.

26 Dec 2024

1718.50

-0.53%

SAST

WOCKHARDT LTD. - 532300 - Closure of Trading Window

BSE India

This is to inform you that pursuant to Company''s Code of Conduct for regulating, monitoring and reporting trading by Designated persons, the trading window for dealing in the equity shares of the Company will be closed from 1st January, 2025 until 48 hours after the declaration of unaudited financial results for quarter and nine months ended on 31st December, 2024.

pdf